EX-FILING FEES
Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Amylyx Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered |
Proposed Price Per |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee(1) |
Carry Forward Form Type |
Carry Forward File Number |
Carry Forward Date |
Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |||||||||||||
| Newly Registered Securities | ||||||||||||||||||||||||
| Primary Offering of Securities: | ||||||||||||||||||||||||
| Fees to Be Paid | Equity | Common Stock, par value $0.0001 per share |
457(o) and 457(r) |
19,714,285 (2) | $3.50 | $68,999,997.50 | 0.0001531 | $10,563.90 | ||||||||||||||||
| Fees Previously Paid | — | — | — | — | — | — | — | |||||||||||||||||
| Carry Forward Securities | ||||||||||||||||||||||||
| Carry Forward Securities | — | — | — | — | — | — | — | — | — | |||||||||||||||
| Total Offering Amounts | $68,999,997.50 | $10,563.90 | ||||||||||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||||||||||
| Total Fee Offsets | ||||||||||||||||||||||||
| Net Fee Due | $10,563.90 | |||||||||||||||||||||||
| (1) | The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”), based on the proposed maximum aggregate offering price, and Rule 457(r) under the Securities Act. In accordance with Rules 456(b) and 457(r) under the Securities Act, the Registrant initially deferred payment of all of the registration fee for Registration Statement on Form S-3ASR (Registration No. 333-270505), which was filed with the Securities and Exchange Commission on March 13, 2023. |
| (2) | Includes 2,571,428 shares of common stock that the underwriter has an option to purchase. |